We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+9.67%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$98.6B
AUM Growth
+$9.82B
(+11%)
Cap. Flow
+$3.18B
Cap. Flow
% of AUM
3.23%
Top 10 Holdings %
Top 10 Hldgs %
34.51%
Holding
3,532
New
899
Increased
935
Reduced
953
Closed
698
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$3.93B |
| 2 |
Microsoft
MSFT
|
+$556M |
| 3 |
Cencora
COR
|
+$492M |
| 4 |
Netflix
NFLX
|
+$452M |
| 5 |
Bank of America
BAC
|
+$411M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$636M |
| 2 |
Eli Lilly
LLY
|
+$572M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$502M |
| 4 |
Advanced Micro Devices
AMD
|
+$395M |
| 5 |
CRH
CRH
|
+$379M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.19% |
| 2 | Consumer Discretionary | 12.64% |
| 3 | Healthcare | 9.35% |
| 4 | Financials | 8.34% |
| 5 | Communication Services | 6.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1976
Cartesian Therapeutics
RNAC
$225M
| $867K | ﹤0.01% |
84,806
+2,176
| +3% | +$24.5K |
|
1977
Patria Investments
PAX
$1.79B
| $865K | ﹤0.01% |
59,232
+29,282
| +98% | +$409K |
|
1978
Synchrony
SYF
$25.1B
| $864K | ﹤0.01% |
+12,165
| New | +$881K |
|
1979
SB Financial Group
SBFG
$167M
| $863K | ﹤0.01% |
44,745
+24,652
| +123% | +$501K |
|
1980
Best Buy
BBY
$18.9B
| $862K | ﹤0.01% |
11,400
-500,046
| -98% | -$35.9M |
|
1981
Western Union
WU
$2.58B
| $861K | ﹤0.01% |
+107,800
| New | +$901K |
|
1982
Dave Inc
DAVE
$5.17B
| $860K | ﹤0.01% |
4,315
-38,009
| -90% | -$8.21M |
|
1983
Pricesmart
PSMT
$5.9B
| $859K | ﹤0.01% |
7,091
-38,148
| -84% | -$4.22M |
|
1984
PMV Pharmaceuticals
PMVP
$58.7M
| $858K | ﹤0.01% |
+612,626
| New | +$848K |
|
1985
ZipRecruiter
ZIP
$348M
| $853K | ﹤0.01% |
+202,127
| New | +$945K |
|
1986
Milestone Pharmaceuticals
MIST
$133M
| $850K | ﹤0.01% |
+425,028
| New | +$747K |
|
1987
Qualys
QLYS
$4.78B
| $850K | ﹤0.01% |
6,422
+1,478
| +30% | +$200K |
|
1988
PagerDuty
PD
$795M
| $849K | ﹤0.01% |
51,393
-633,270
| -92% | -$10.1M |
|
1989
Luxfer Holdings
LXFR
$456M
| $845K | ﹤0.01% |
60,793
-111,943
| -65% | -$1.44M |
|
1990
Karyopharm Therapeutics
KPTI
$161M
| $840K | ﹤0.01% |
128,451
| – | – |
|
1991
Lifecore Biomedical
LFCR
$165M
| $840K | ﹤0.01% |
114,075
+78,723
| +223% | +$596K |
|
1992
PUT
Align Technology
ALGN
$12.6B
| $839K | ﹤0.01% |
+6,700
| New | +$1.05M |
|
1993
Aldeyra Therapeutics
ALDX
$95.3M
| $836K | ﹤0.01% |
+160,213
| New | +$835K |
|
1994
VanEck Pharmaceutical ETF
PPH
$987M
| $833K | ﹤0.01% |
+9,214
| New | +$807K |
|
1995
Surgery Partners
SGRY
$2.04B
| $828K | ﹤0.01% |
+38,241
| New | +$853K |
|
1996
American Healthcare REIT
AHR
$11.1B
| $827K | ﹤0.01% |
19,696
-128,104
| -87% | -$5.15M |
|
|
BCIC
1997
BCP Investment Corp
BCIC
$88.3M
| $826K | ﹤0.01% |
71,662
+6,027
| +9% | +$74.2K |
|
1998
CALL
Thermo Fisher Scientific
TMO
$214B
| $825K | ﹤0.01% |
+1,700
| New | +$791K |
|
1999
SGHC Ltd
SGHC
$7.62B
| $824K | ﹤0.01% |
+62,400
| New | +$734K |
|
|
JMIA
2000
Jumia Technologies
JMIA
$741M
| $823K | ﹤0.01% |
70,868
-987,247
| -93% | -$7.22M |
|
Similar funds
Marshall Wace's Q3 2025 Portfolio in Review
As of Q3 2025, Marshall Wace held 3,532 positions worth $98.6B, up 11% from $88.8B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Marshall Wace deployed $3.18B of net new capital in Q3 2025, opening 899 new positions and adding to 935 existing holdings. Its largest new stake was Texas Instruments: 1,537,539 shares worth $282M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $636M trimmed.
- Marshall Wace's largest Q3 2025 buy was Texas Instruments: 1,537,539 shares worth $282M.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q3 2025, an estimated $3.93B increase.
- Marshall Wace's biggest Q3 2025 reduction was Alphabet (Google) Class A, cutting an estimated $636M.
- Marshall Wace fully exited AT&T in Q3 2025, selling an estimated $235M.
- Marshall Wace's ten largest holdings make up 35% of its $98.6B portfolio in Q3 2025.
- Marshall Wace opened 899 new positions and closed 698 in Q3 2025.
- Marshall Wace's portfolio value rose 11% quarter-over-quarter to $98.6B.
Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.